psychopharmacologic drugs advisory committee pdac december 13 2006 introductory comments n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Psychopharmacologic Drugs Advisory Committee (PDAC) December 13, 2006 Introductory Comments PowerPoint Presentation
Download Presentation
Psychopharmacologic Drugs Advisory Committee (PDAC) December 13, 2006 Introductory Comments

Loading in 2 Seconds...

  share
play fullscreen
1 / 7
corin

Psychopharmacologic Drugs Advisory Committee (PDAC) December 13, 2006 Introductory Comments - PowerPoint PPT Presentation

146 Views
Download Presentation
Psychopharmacologic Drugs Advisory Committee (PDAC) December 13, 2006 Introductory Comments
An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Psychopharmacologic Drugs Advisory Committee (PDAC)December 13, 2006Introductory Comments Thomas Laughren, M.D. Director, Division of Psychiatry Products Food and Drug Administration

  2. Standard Language inAntidepressant Labeling • “Suicide: The possibility of a suicide attempt is inherent in major depressive disorder and may persist until significant remission occurs. Close supervision of high-risk patients should accompany initial drug therapy. Prescriptions for Drug X should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.”

  3. Clinical Psychiatry, by Mayer-Gross, Slater, and Roth, London, 1960, p. 231 • “With beginning convalescence (following initiation of treatment with tricyclic antidepressants), the risk of suicide once more becomes serious as retardation fades.”

  4. Earlier Analyses ofAdult Suicidality Data • Beasley, et al, 1991 • Khan, et al, 2000 • Storosum, et al, 2001 • Hammad, et al, 2006

  5. FDA Regulatory Actions Based on Pediatric Suicidality Data • New warning language (including box) and medguide • Notes increased risk of suicidality in short-term pbo-controlled antidepressant trials (4% vs 2%) • Notes no completed suicides • Advice: balance risk with clinical need • Prescribers should observe for worsening, suicidality, or unusual changes • Families should also observe for change and communicate with prescriber

  6. BMJ Papers on Adult SuicidalityFebruary 17, 2005 • Fergusson, et al, 2005 • Systematic review; published reports of pbo-controlled trials for antidepressants • Gunnell, et al, 2005 • Systematic review; summary data for pbo-controlled trials for SSRIs, from MHRA website • Martinez, et al, 2005 • Nested case control study; GPRD

  7. Goals of Today’s Meeting • FDA will present findings from meta-analysis of adult suicidality data • FDA will provide interpretation of these data • FDA will briefly outline plans for labeling modifications based on new findings • We request discussion and general comments on findings and FDA plans